Vulvovaginal candidiasis (VVC) : A review of the literature

Lidya Trisna Dewi

Lidya Trisna Dewi
Faculty of Medicine, Udayana University-Denpasar. Email:
Online First: June 01, 2020 | Cite this Article
Dewi, L. 2020. Vulvovaginal candidiasis (VVC) : A review of the literature. Bali Dermatology and Venereology Journal 3(1). DOI:10.15562/bdv.v3i1.37

Vulvovaginal Candidiasis (VVC) is the second most common cause of vaginitis after bacterial vaginosis. VVC often occurs in women of reproductive age (20-40 years). Risk factors for VVC can be divided into two, such as host factors (pregnancy, hormone replacement, uncontrolled diabetes mellitus, immunosuppression, antibiotics, use of glucocorticoids, genetic influences) and behavioral factors (oral   contraceptives, cotraceptives and also some sexual habits, hygiene, and clothes that are used). To diagnose VVC in a person, evaluation from anamnesis and clinical manifestation can be conducted. It can also be confirmed by laboratory examination. The management based on the classification. Uncomplicated VVC is most effectively treated with topical azoles, but a single dose of fluconazole can also be given orally. Treatment of VVC with complications can be given fluconazole 150 mg for 3 days or topical azole for 7 days. However, when the VVC case that caused by Candida non-albicans not responding to conventional treatment such as antimycotics, the   amphotericin B can be given to cure the disease. VVC caused by Candida glabrata can be given topical boric acid or flucytosine. This article consists of several theoretical references that has been viewed to have a better understanding regarding candidiasis vulvovaginitis.



Arfiputri DS, Hidayati AN, Handayani S, Erviant E. Risk Factors Of Vulvovaginal Candidiasis In Dermato-Venereology Outpatients Clinic Of Soetomo General Hospital, Surabaya, Indonesia. J. Infect. 2018 March 07;12(S):90-94 12v1S.13

Goncalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, and Silva N. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit Rev Microbiol, 2016; 42(6):90592 DOI:10.3109/1040841X .2015.109180

Dovnik A, Golle A , Novak D , Arko D , Takac I. Treatment of vulvovaginal candidiasis: a review of the literature.Acta Dermatovenerol APA. 2015; 24:5-7 doi:10.15570/actaapa. 2015.2

Zeng X, Zhang Y, Zhang T, Xue Y, Xu H, An R. Risk Factors of Vulvovaginal Candidiasis among Women of Reproductive Age in Xi’an: A Cross-Sectional Study.Hindawi. 2018;8

Cassone A. Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects. BJOG 2015; 122:785–794. DOI:10.1111/1471-0528.12994

Yano J, Sobel JD, Nyirjesy P, Sobel R, Valerie L. Williams VL, Yu Q, Noverr MC and Paul L. Fidel PL. Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. BMC Women's Health. 2019 ; 19:48

Mendling W, Schlegelmilch R. Three-day combination treatment for vulvovaginal vaginosis with 200mg clotrimazol vaginal suppositories and clotrimazol cream for the vulva is significantly better than treatment with vaginal suppositories alone–an earlier, multi-centre, placebo-controlled double blind study. Geburtshilfe Frauenheilkd. 2014 Apr; 74(4): 355–360 doi: 10.1055/s-0034-1368243

Garg A, Kundu R. Yeast infections : Candidiasis, tinea (pityriasis) versikolor and malassezia (pityrosporum) folliculitis. In : Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffel DJ, editors. FItzpatrics’s dermatology in general medicine. 8th. New York: McGraw-Hill; 2012. p. 2299-2306.

Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review.Lancet Infect Dis. 2018;18(11):30103 (18)30103-8

No Supplementary Material available for this article.
Article Views      : 269
PDF Downloads : 120

Related Articles

Search Authors in

  • Lidya Trisna Dewi

  • Lidya Trisna Dewi

  • Lidya Trisna Dewi